First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers.
Authors:
- S. K. SandhuSSS. K. Sandhu
- R. M. WenhamRWR. M. Wenham
- G. WildingGWG. Wilding
- M. McFaddenMMM. McFadden
- L. SunLSL. Sun
- C. ToniattiCTC. Toniatti
- M. StrohMSM. Stroh
- C. L. CarpenterCCC. L. Carpenter
- J. S. De BonoJBJ. S. De Bono
- W. R. SchelmanWSW. R. Schelman
- 20 May 2010
- journal article
- abstracts
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15_suppl) , 3001